Search results
Efforts to reduce the mortality rates and damage from ANCA-associated vasculitis are directed toward diagnosis early in the disease course, instituting appropriate immunosuppression swiftly, and limiting toxicity from glucocorticoids, which remain an essential part of therapeutic regimens.
These medications may include methotrexate (Trexall), azathioprine (Imuran, Azasan), mycophenolate (CellCept), cyclophosphamide, tocilizumab (Actemra) or rituximab (Rituxan). The specific medications that you'll need depend on the type and severity of vasculitis you have, which organs are involved, and any other medical problems that you have.
May 22, 2023 · Treatment for vasculitis includes using steroids along with other medication the suppress the immune system, such as cyclophosphamide or rituximab.
Jan 16, 2012 · Consider antineutrophil cytoplasmic antibody (ANCA) associated vasculitis when inflammatory disease cannot be ascribed to any other disease and inflammation progresses despite antibiotics. Avoid diagnostic delay to prevent end organ damage, particularly renal disease.
Apr 1, 2021 · From a therapeutic perspective, multiple targets have been identified for currently approved therapies and/or future directions, as treatment of ANCA-associated vasculitis becomes more precise and personalized, aiming to minimize the risks of therapy.
Since the publication of the EULAR recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)- associated vasculitis (AAV) in 2016, several randomised clinical trials have been published that have the potential to change clinical care and support the need for an update. Methods.
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis consists of two main diseases, granulomatosis with polyangiitis and microscopic polyangiitis, and remains among the most devastating and potentially lethal forms of autoimmune inflammatory disease.
